Cancer Biomarkers Market Size, Share, Strategic Outlook, 2026-2034
Market Overview
According to fortune business insights, The global cancer biomarkers market size was valued at USD 42.87 billion in 2025. It is projected to grow from USD 48.2 billion in 2026 to USD 83.61 billion by 2034, exhibiting a CAGR of 7.13% during the forecast period. North America dominated the cancer biomarkers market with a market share of 35.94% in 2025.
The analysis shows that the market is driven by the increasing global incidence of cancer, expanding research, and technological advancements. Cancer biomarkers, which are molecules indicating the presence of cancer, are crucial for early detection, non-invasive diagnosis, personalized medicine, and drug discovery and development. The growing demand for these applications is boosting market growth worldwide.
Major Players Profiled in the Market Report:
• F. Hoffmann-La Roche Ltd.
• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• CENTOGENE N.V.
• Axon Medchem
• Sino Biological Inc.
• R&D System
• BioVision Inc.
• Myriad RBM
• Other players
Segments
Breast Cancer Segment to Hold Largest Share due to High Prevalence
Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment is expected to hold the largest market share (32.59% in 2026), driven by its high prevalence, rising awareness, and increasing research activities focused on new detection biomarkers.
HER-2 Biomarker Segment to Dominate the Market
By biomarker type, the market is categorized into PSA, HER-2, EGFR, KRAS, and others. The HER-2 segment is projected to hold the largest share (33.34% in 2026) due to the rising prevalence of breast cancer and the introduction of new biomarker-based tests, such as liquid biopsies, for its diagnosis.
Diagnostics & Research Laboratories to Lead the Market
Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, diagnostics & research laboratories, hospitals & specialty clinics, and others. The diagnostics & research laboratories segment is projected to hold the dominant market share (53.49% in 2026) owing to the introduction of new diagnostic products and the increasing number of tests being performed.
Source: https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630
Drivers & Restraints
Rising Prevalence of Cancer to Fuel Market Growth
The increasing global incidence of cancer is a primary driver for the market. As cancer rates rise, so does the demand for early and accurate diagnosis, personalized treatment plans, and effective drug development, all of which heavily rely on cancer biomarkers. This rising demand is propelling the growth of the market in both emerging and developed countries.
Presence of Potential Pipeline Candidates to Boost the Market
The market is being significantly boosted by robust research and development activities. Pharmaceutical companies are actively investing in novel biomarkers, with a large number of potential candidates currently in the late stages of clinical trials. The successful launch of these new biomarkers for cancer screening and diagnosis is anticipated to provide a tremendous boost to market growth.
However, the market's growth is restrained by a lack of reimbursement policies for biomarker testing in many countries. This, combined with the high cost of diagnosis and treatment, limits patient access and can lead to a preference for lower-cost detection methods, thereby restricting the use of advanced cancer biomarkers.
Regional Insights
High Healthcare Spending and R&D Propels Market in North America
North America holds the dominant market share, valued at USD 15.41 billion in 2025. The region's leadership is supported by a well-established regulatory framework, rapid clinical adoption of advanced technologies like next-generation sequencing, and high healthcare spending. Sustained investment in oncology drug discovery, development, and diagnostics reinforces the strong demand.
Asia Pacific is anticipated to be the fastest-growing region, driven by the accelerating uptake of biomarker-based diagnostics, rising cancer incidence, and increasing investment in oncology research.
Europe is the second-largest market, with growth fueled by expanding precision medicine initiatives and the increasing integration of biomarker testing into routine oncology care.
Cancer Biomarkers Market Future Growth
The cancer biomarkers market is on a strong growth trajectory, primarily fueled by the paradigm shift toward personalized medicine. As the "one-size-fits-all" approach to cancer treatment becomes obsolete, biomarkers are becoming essential for diagnosing specific cancer subtypes, predicting patient prognosis, and selecting targeted therapies that are more effective and have fewer side effects. The continuous development and identification of novel biomarkers, supported by technological advancements in genomics and proteomics, are vital for this shift. With a rich pipeline of candidates and increasing collaborations between research institutions and industry players, biomarkers are set to redefine cancer care, driving significant market expansion in the coming years.
Competitive Landscape
Key Players Focus on Novel Test Introduction and Strategic Collaborations
The cancer biomarkers market is semi-consolidated, with leading players like F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc. holding significant shares. These companies are focused on strengthening their market position by introducing novel biomarker tests and pursuing strategic mergers, acquisitions, and collaborations. This approach aims to expand their product portfolios, enhance their brand presence, and drive innovation in the field of oncology diagnostics.
Key Industry Development:
• March 2021: Roche received FDA approval for its VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify lung cancer patients eligible for specific targeted treatments, enabling quicker and more effective care.
• July 2020: Thermo Fisher Scientific signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical to expand the use of its Oncomine Dx Target Test in Japan, aiming to accelerate local biomarker testing for lung cancer patients.